LY364947, a small TGF-βR1 inhibitor, was shown to reprogram intratumor CD8+ T cells and Tregs and sensitize tumor cells to ICIs by increasing expression of PD-L1 (43). This evidence concerns the gene TGFBR1 and neoplasm.